Tryp Therapeutics Inc (TRYPF) Corporate Presentation

Corporate Presentation Fall 2021 OUR SOLUTIONS: TRP-8803 (PROPRIETARY, PSILOCYBIN-BASED FORMULATION) TRP-8803 is a proprietary psilocybin-based drug product manufactured exclusively for Tryp by Curia and Alcami. The novel formulation and route of administration are expected to improve the patient experience and to enhance patient safety. We expect TRPՓ8803 to be used for Tryp’s Phase 2b clinical trials and beyond. Tryp expects to use multiple data sets to support the use of TRPՓ8803 in Phase 2b studies and eventual commercialization, including: ● Preclinical data for TRPՓ8803 ● Clinical pharmacology data for TRPՓ8803 ● Phase 2a data for TRPՓ8802 Preclinical and Phase 1 data for TRPՓ8803 is being generated in partnership with the University of Michigan and Calvert Labs. Additional details of TRPՓ8803 will be disclosed in 1Q 2022 once additional intellectual property filings for the product have been submitted. 17